TD Cowen Raises GLP-1 Market Forecast to $150B by 2030, Up from $139B

According to TD Cowen, the brokerage upgraded its 2030 forecast for global diabetes and obesity drug sales to $150 billion, up from the previous estimate of $139 billion. This represents a 14% compound annual growth rate from 2025 onwards. The number of patients receiving treatment is expected to grow from 46 million in 2025 to 59 million by 2030.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments